As of December 31, 2025, Eurofins Scientific SE carries a market capitalization of 185.37B, placing it among publicly traded companies globally. Its enterprise value stands at 263.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 185.37B |
| Enterprise Value | 263.09B |
Eurofins Scientific SE's next confirmed earnings release is scheduled for March 2, 2027.
| Earnings Date | 3/2/2027 |
As of December 31, 2025, Eurofins Scientific SE has 176.70M shares outstanding.
| Shares Outstanding | 176.70M |
These figures are as of December 31, 2025.
| PB Ratio | 1.93 |
| P/TBV Ratio | -10.90 |
As of December 31, 2025, Eurofins Scientific SE maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.09 |
| Quick Ratio | 0.33 |
| Debt / Equity | 96.84 |
These figures cover the twelve months ended December 31, 2025.
| Employee Count | 64,195.00 |
As of the close on November 4, 2026, Eurofins Scientific SE's stock has gained approximately 0.00% over the past 52 weeks.
| 50-Day Moving Average | 1,035.06 |
As of December 31, 2025, Eurofins Scientific SE holds 16.74B in cash and equivalents against 93.74B in total debt, resulting in a net debt position of 67.79B. Total book value stands at 96.10B, with working capital of 4.74B providing operational flexibility.
| Cash & Cash Equivalents | 16.74B |
| Total Debt | 93.74B |
| Net Debt | 67.79B |
| Equity (Book Value) | 96.10B |
| Book Value Per Share | 543.86 |
| Working Capital | 4.74B |
Eurofins Scientific SE's most recent stock split took place on November 19, 2020 with a 1:10 split ratio.
| Last Split Date | 11/19/2020 |
| Split Ratio | 1:10 |
Already premium?